LAS VEGAS, Nov. 7 /PRNewswire-FirstCall/ -- VMT Scientific Inc. (OTC: VMTF) VMT Scientific is proud to announce that Jacques D. Barth, MD, PhD, FACC, FAHA has agreed to accept the position as Primary Investigator (PI) for the VasCir(TM) program study to culminate in FDA approval. Bryan McGlynn, VP of Medical Research for VMT Scientific, with over thirty-five years of medical research experience, will coordinate with Dr. Barth's efforts. Dr. Barth stated he is excited about being part of this history making technology known as the VasCir(TM). VMT Scientific is also looking forward to its technology being scrutinized by Dr. Barth's advanced vascular image processing technology. VMT Scientific is dedicated to proving efficacy and educating Diabetics about the VasCir(TM) device. We believe attracting and working with dedicated physician researchers will enable VMT Scientific, Inc. to forge ahead towards one day bringing this technology to the world. We encourage everyone to visit our website http://www.vmtf.com/ and take our virtual tour about this technology and its objectives in treating peripheral vascular disease. This Press Release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should not place undue reliance on these forward-looking statements. These statements involve risks and uncertainties that could cause actual results to differ materially from those suggested in the forward- looking statements, particularly those risks and uncertainties inherent in the process of developing, manufacturing and distributing medical products and Clinical trials. Factors that may cause such a difference include risks related to VMT Scientific Inc.'s limited operating history, risks associated with completing development and obtaining FDA medical approvals, successful patent protection and prosecution, successful sale of licensed technology nationally or internationally. VMT Scientific technology will not meet with market acceptance, the risk of future warranty and product liability claims, the uncertainty of VMT Scientifics' future access to capital to sustain operations, achieve profitability or continue as a going concern, the failure by VMT Scientifics' to secure and maintain relationships with suppliers, manufacturers and other third parties, reliance on key employees, and dependence on intellectual property. These forward-looking statements are based on information and management's expectations as of the date hereof. Future results may differ materially from our current expectations. DATASOURCE: VMT Scientific, Inc. CONTACT: Catherine S. Ratelle, Director of Operations at VMT Scientific, Inc., +1-702-990-3477, Web site: http://www.vmtf.com/

Copyright